Allergic bronchopulmonary aspergillosis in children

Sara Manti, Giuseppe Fabio Parisi, Maria Papale, Amelia Licari, Elena Chiappini, Enza Mulè, Novella Rotolo, Salvatore Leonardi

Research output: Contribution to journalArticlepeer-review


Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disease caused by Aspergillus induced hypersensitivity that occurs in immunocompetent but susceptible patients with asthma and/or cystic fibrosis (CF). In children, ABPA remains mostly undiagnosed resulting in one of the most common causes of poorly controlled asthma and highly significant morbidity in children with CF. Currently, no specific diagnostic criteria of ABPA for children are available. Corticosteroids and itraconazole are the mainstays of therapy although there is a lack of randomized clinical trials regarding their usefulness for ABPA in children. Several monoclonal antibodies, such as omalizumab and mepolizumab, may be potential therapies for refractory ABPA in pediatric patients; however, further data are required to clarify the optimal dose and duration of therapy as a routine treatment approach.

Original languageEnglish
Pages (from-to)20-22
Number of pages3
JournalPediatric Allergy and Immunology
Issue numberS26
Publication statusPublished - Nov 2020


  • allergic bronchopulmonary aspergillosis
  • asthma
  • children
  • cystic fibrosis

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Allergic bronchopulmonary aspergillosis in children'. Together they form a unique fingerprint.

Cite this